C-Reactive Protein and the Risk of Incident Colorectal Cancer

JAMA

Volumn 291, Issue 5, 2004, Pages 585-590

  Erlinger, Thomas P ^a,c   Platz, Elizabeth A ^b,c   Rifai, Nader ^d   Helzlsouer, Kathy J ^a,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENT COLORECTAL CANCER; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; UNITED STATES; BLOOD; CASE CONTROL STUDY; COLORECTAL TUMOR; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 1342288777     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.5.585     Document Type: Article

References (25)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
2. Levin B. Inflammatory bowel disease and colon cancer. Cancer. 1992;70(5 suppl):1313-1316.
3. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-899.
4. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-890.
5. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993; 328:1313-1316.
6. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991;101:635-639.
7. Laden heim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology. 1995;108:1083-1087.
8. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342: 1946-1952.
9. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
10. Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but non-specific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol. 2000;20:1047-1051.
11. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506-512.
12. Grimm RH Jr, Neaton JD, Ludwig W. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA. 1985; 254:1932-1937.
13. Friedman GD, Fireman BH. The leukocyte count and cancer mortality. Am J Epidemiol. 1991;133:376-380.
14. Yano K, Grove JS, Chen R, et al. Plasma fibrinogen as a predictor of total and cause-specific mortality in elderly Japanese-American men. Arterioscler Thromb Vasc Biol. 2001;21:1065-1070.
15. Rifal N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136-2141.
16. Das I. Raised C-reactive protein levels in serum from smokers. Clin Chim Acta. 1985;153:9-13.
17. Levin B. Inflammatory bowel disease and colon cancer. Cancer. 1992;70(5 suppl):1313-1316.
18. Okada F, Kawaguchi T, Habelhah H, et al. Conversion of human colonic adenoma cells to adenocarcinoma cells through inflammation in nude mice. Lab Invest. 2000;80:1617-1628.
19. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett. 2000;151:31-38.
20. Rifai N, Buring JE, Lee IM, Manson JE, Ridker PM. Is C-reactive protein specific for vascular disease in women? Ann Intern Med. 2002;136:529-533.
21. Ko WF, Helzlsouer KJ, Comstock GW. Serum albumin, bilirubin, and uric acid and the anatomic site-specific incidence of colon cancer. J Natl Cancer Inst. 1994;86:1874-1875.
22. Tracy RP, Psaty BM, Macy E, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997;17:2167-2176.
23. SoRelle R. Weight loss decreases C-reactive protein levels. Circulation. 2002;105:E9071-E9072.
24. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002;105:564-569.
25. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.